Synergistic anticancer effects of Pam3CSK4 and Ara-C on B-cell lymphoma cells.
about
Vaccine adjuvants as potential cancer immunotherapeuticsThe Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells.Use of adjuvants for immunotherapy.Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma.Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.Synergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model.
P2860
Synergistic anticancer effects of Pam3CSK4 and Ara-C on B-cell lymphoma cells.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Synergistic anticancer effects of Pam3CSK4 and Ara-C on B-cell lymphoma cells.
@en
type
label
Synergistic anticancer effects of Pam3CSK4 and Ara-C on B-cell lymphoma cells.
@en
prefLabel
Synergistic anticancer effects of Pam3CSK4 and Ara-C on B-cell lymphoma cells.
@en
P2093
P1476
Synergistic anticancer effects of Pam3CSK4 and Ara-C on B-cell lymphoma cells.
@en
P2093
Cheryl A P Ma
Jyh Y Chwee
Nina Le Bert
Sae-Kyung Lee
P304
P356
10.1158/1078-0432.CCR-13-2522
P407
P577
2014-05-05T00:00:00Z